Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. The company is headquartered in Schlieren, Zuerich and currently employs 122 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Follow-Up Questions
Kuros Biosciences AG의 CEO는 누구입니까?
Mr. Chris Fair은 2021부터 회사에 합류한 Kuros Biosciences AG의 Chief Executive Officer입니다.
CSBTF 주식의 가격 성능은 어떻습니까?
CSBTF의 현재 가격은 $41이며, 전 거래일에 decreased 0% 하였습니다.
Kuros Biosciences AG의 주요 사업 주제나 업종은 무엇입니까?
Kuros Biosciences AG은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Kuros Biosciences AG의 시가총액은 얼마입니까?
Kuros Biosciences AG의 현재 시가총액은 $1.5B입니다
Kuros Biosciences AG는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Kuros Biosciences AG에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
